| GGLCX | OSMAX | GGLCX / OSMAX | |
| Total Expense Ratio | 0.91 | 1.37 | 66% |
| Annual Report Gross Expense Ratio | 4.40 | 1.37 | 321% |
| Fund Existence | 24 years | 28 years | - |
| Gain YTD | 5.971 | 2.817 | 212% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 1000 | 1000 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 7.27M | 2.56B | 0% |
| Annual Yield % from dividends | 2.01 | 1.40 | 144% |
| Returns for 1 year | 46.05 | -2.47 | -1,863% |
| Returns for 3 years | 41.44 | -12.49 | -332% |
| Returns for 5 years | 15.97 | -31.87 | -50% |
| Returns for 10 years | -23.14 | 12.55 | -184% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| AIORX | 12.51 | 0.18 | +1.46% |
| American Century International Opps R | |||
| FVALX | 6.16 | 0.06 | +0.98% |
| Forester Value N | |||
| GIDUX | 9.01 | 0.01 | +0.11% |
| Goldman Sachs Intl Eq Div & Prem R6 | |||
| GIEZX | 16.49 | N/A | N/A |
| GuideStone Funds International Eq Inv | |||
| JAGLX | 81.26 | -0.51 | -0.62% |
| Janus Henderson Global Life Sciences T | |||